Kairos Pharma, LTD.

Kairos Pharma, LTD. (KAPA) priced its initial public offering on Sep 17, 2024 at $4.00 per share, raising $6.2M, and listed on NYSE American. At the IPO price its market capitalization was about $51.4M. Boustead was lead-left underwriter, joined by EF Hutton and Sutter. Dorsey & Whitney advised the company and Olshan Frome Wolosky advised the underwriters.

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing cancer therapeutics designed to overcome immune suppression and drug resistance. Its antibodies and small molecules are aimed at prostate, lung and breast cancer and glioblastoma.

Status

IPO

Ticker

KAPA

Exchange

NYSE American

Priced

Sep 17, 2024

IPO price

$4.00

Raised

$6.2M

Market cap at IPO price

$51.4M

First filed

Sep 29, 2023

Underwriters

Boustead, EF Hutton and Sutter

Company counsel

Dorsey & Whitney

Underwriters' counsel

Olshan Frome Wolosky

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.